Journey Drug Patent Portfolio
Journey owns 4 orange book drugs protected by 31 US patents Given below is the list of Journey's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10398641 | Compositions and methods for treating rosacea and acne | 08 Sep, 2037 | Active |
US10849847 | Compositions and methods for treating rosacea and acne | 08 Sep, 2037 | Active |
US10004717 | Glycopyrrolate salts | 28 Feb, 2033 | Active |
US10543192 | Glycopyrrolate salts | 28 Feb, 2033 | Active |
US10548875 | Glycopyrrolate salts | 28 Feb, 2033 | Active |
US8859610 | Crystalline glycopyrrolate tosylate | 28 Feb, 2033 | Active |
US9006462 | Glycopyrrolate salts | 28 Feb, 2033 | Active |
US9259414 | Glycopyrrolate salts | 28 Feb, 2033 | Active |
US10086080 | Topical tetracycline compositions | 01 Oct, 2030 | Active |
US10137200 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | 01 Oct, 2030 | Active |
US10213512 | Topical tetracycline compositions | 01 Oct, 2030 | Active |
US10265404 | Compositions, gels and foams with rheology modulators and uses thereof | 01 Oct, 2030 | Active |
US10517882 | Method for healing of an infected acne lesion without scarring | 01 Oct, 2030 | Active |
US10821187 | Compositions, gels and foams with rheology modulators and uses thereof | 01 Oct, 2030 | Active |
US8865139 | Topical tetracycline compositions | 01 Oct, 2030 | Active |
US8945516 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | 01 Oct, 2030 | Active |
US8992896 | Topical tetracycline compositions | 01 Oct, 2030 | Active |
US9675700 | Topical tetracycline compositions | 01 Oct, 2030 | Active |
US10322186 | Topical tetracycline compositions | 01 Oct, 2030 | Active |
US10946101 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | 01 Oct, 2030 | Active |
US9744105 | Topical glycopyrrolate formulations | 18 Jul, 2030 | Active |
US8618160 | Topical glycopyrrolate formulations | 10 Dec, 2029 | Active |
US10052267 | Topical glycopyrrolate formulations | 17 Oct, 2028 | Active |
US7541347 | Minocycline oral dosage forms for the treatment of acne | 02 Apr, 2027 | Active |
US7544373 | Minocycline oral dosage forms for the treatment of acne | 02 Apr, 2027 | Active |
US7919483 | Method for the treatment of acne | 07 Mar, 2027 | Active |
US7790705 | Minocycline oral dosage forms for the treatment of acne | 24 Jun, 2025 | Active |
US8252776 | Minocycline oral dosage forms for the treatment of acne | 24 Jun, 2025 | Active |
US8268804 | Minocycline oral dosage forms for the treatment of acne | 24 Jun, 2025 | Active |
US6433003 | Method for treating hyperhidrosis in mammals | 10 Apr, 2020 | Expired |
US5908838 | Method for the treatment of acne | 19 Feb, 2018 | Expired |
Latest Legal Activities on Journey's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Journey.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 4th Yr, Small Entity | 03 Jun, 2024 | US10849847 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 03 May, 2024 | US10821187 |
Payment of Maintenance Fee, 12th Year, Large Entity | 20 Feb, 2024 | US8268804 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8252776 (Litigated) |
Requirement for information sent under 37 CFR 1.750 | 22 Jan, 2024 | US8618160 |
Email Notification
Critical
| 07 Sep, 2023 | US8992896 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 07 Sep, 2023 | US8992896 |
Payment of Maintenance Fee, 4th Year, Large Entity | 04 Aug, 2023 | US10548875 |
Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jul, 2023 | US10543192 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Jun, 2023 | US10517882 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 22 May, 2023 | US8992896 |
Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted
Critical
| 22 May, 2023 | US8992896 |
Petition to Accept Late Payment of Maintenance Fee Payment Filed
Critical
| 22 May, 2023 | US8992896 |
Petition Decision - Accept Late Payment of Maintenance Fees - Granted
Critical
| 22 May, 2023 | US8992896 |
Surcharge, Petition to Accept Pymt After Exp, Unintentional. | 22 May, 2023 | US8992896 |
Journey's Family Patents
Journey Drug List
Given below is the complete list of Journey's drugs and the patents protecting them.
1. Amzeeq
Amzeeq is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10398641 | Compositions and methods for treating rosacea and acne |
08 Sep, 2037
(12 years from now)
| Active |
US10849847 | Compositions and methods for treating rosacea and acne |
08 Sep, 2037
(12 years from now)
| Active |
US10086080 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US10137200 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
01 Oct, 2030
(5 years from now)
| Active |
US10213512 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US10265404 | Compositions, gels and foams with rheology modulators and uses thereof |
01 Oct, 2030
(5 years from now)
| Active |
US10517882 | Method for healing of an infected acne lesion without scarring |
01 Oct, 2030
(5 years from now)
| Active |
US10821187 | Compositions, gels and foams with rheology modulators and uses thereof |
01 Oct, 2030
(5 years from now)
| Active |
US8865139 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US8945516 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
01 Oct, 2030
(5 years from now)
| Active |
US8992896 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US9675700 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amzeeq's drug page
2. Qbrexza
Qbrexza is protected by 10 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10004717 | Glycopyrrolate salts |
28 Feb, 2033
(8 years from now)
| Active |
US10543192 | Glycopyrrolate salts |
28 Feb, 2033
(8 years from now)
| Active |
US10548875 | Glycopyrrolate salts |
28 Feb, 2033
(8 years from now)
| Active |
US8859610 | Crystalline glycopyrrolate tosylate |
28 Feb, 2033
(8 years from now)
| Active |
US9006462 | Glycopyrrolate salts |
28 Feb, 2033
(8 years from now)
| Active |
US9259414 | Glycopyrrolate salts |
28 Feb, 2033
(8 years from now)
| Active |
US9744105 | Topical glycopyrrolate formulations |
18 Jul, 2030
(5 years from now)
| Active |
US8618160 | Topical glycopyrrolate formulations |
10 Dec, 2029
(5 years from now)
| Active |
US10052267 | Topical glycopyrrolate formulations |
17 Oct, 2028
(4 years from now)
| Active |
US6433003 | Method for treating hyperhidrosis in mammals |
10 Apr, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qbrexza's drug page
3. Ximino
Ximino is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7541347 | Minocycline oral dosage forms for the treatment of acne |
02 Apr, 2027
(2 years from now)
| Active |
US7544373 | Minocycline oral dosage forms for the treatment of acne |
02 Apr, 2027
(2 years from now)
| Active |
US7919483 | Method for the treatment of acne |
07 Mar, 2027
(2 years from now)
| Active |
US7790705 | Minocycline oral dosage forms for the treatment of acne |
24 Jun, 2025
(8 months from now)
| Active |
US8252776 | Minocycline oral dosage forms for the treatment of acne |
24 Jun, 2025
(8 months from now)
| Active |
US8268804 | Minocycline oral dosage forms for the treatment of acne |
24 Jun, 2025
(8 months from now)
| Active |
US5908838 | Method for the treatment of acne |
19 Feb, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ximino's drug page
4. Zilxi
Zilxi is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10213512 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US10265404 | Compositions, gels and foams with rheology modulators and uses thereof |
01 Oct, 2030
(5 years from now)
| Active |
US10322186 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US10946101 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
01 Oct, 2030
(5 years from now)
| Active |
US8865139 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US8945516 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
01 Oct, 2030
(5 years from now)
| Active |
US8992896 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
US9675700 | Topical tetracycline compositions |
01 Oct, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zilxi's drug page